Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Unicycive Therapeutics, Inc. (NASDAQ:UNCY) have earned a consensus rating of “Moderate Buy” from the seven ratings firms that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and five have given a buy recommendation to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $18.75.

A number of equities research analysts have commented on UNCY shares. Guggenheim reiterated a “buy” rating and issued a $25.00 price target (down from $37.00) on shares of Unicycive Therapeutics in a research report on Thursday, August 13th. B. Riley Financial restated a “buy” rating and set a $20.00 target price (down from $22.00) on shares of Unicycive Therapeutics in a research report on Wednesday, August 12th. Wall Street Zen upgraded Unicycive Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. Benchmark reissued a “speculative buy” rating and issued a $15.00 price target (up from $13.00) on shares of Unicycive Therapeutics in a research note on Thursday, August 20th. Finally, HC Wainwright reduced their price objective on shares of Unicycive Therapeutics from $22.00 to $15.00 and set a “buy” rating for the company in a research report on Tuesday, June 30th.

Unicycive Therapeutics Price Performance

Shares of NASDAQ:UNCY opened at $5.29 on Monday. Unicycive Therapeutics has a 1 year low of $3.71 and a 1 year high of $8.74. The stock has a market capitalization of $147.33 million, a price-to-earnings ratio of -3.02 and a beta of 1.79. The company’s 50 day simple moving average is $5.27 and its 200 day simple moving average is $6.48.

Unicycive Therapeutics (NASDAQ:UNCY) last issued its earnings results on Wednesday, August 12th. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.47) by $0.41. As a group, analysts anticipate that Unicycive Therapeutics will post -1.17 EPS for the current fiscal year.

Unicycive Therapeutics News Summary

Here are the key news stories impacting Unicycive Therapeutics this week:

• Negative Sentiment: Several firms, including Kaplan Fox, Bronstein Gewirtz & Grossman, Levi & Korsinsky, and Faruqi & Faruqi, reminded investors that a class action has been filed against Unicycive and certain officers. The case covers investors who purchased securities from December 29, 2025, through June 29, 2026, with November 2, 2026, set as the deadline to seek lead-plaintiff status. Kaplan Fox class action notice
• Negative Sentiment: The lawsuit-related notices allege that Unicycive misled investors about the timing of an FDA decision for oxylanthanum carbonate and the potential commercial launch of the kidney-disease treatment. The allegations also claim the company had not inspected a third-party manufacturing facility that had previously contributed to a Complete Response Letter. These claims have not been proven in court. Unicycive shareholder alert
• Negative Sentiment: The volume of law-firm announcements over the past two days increases the visibility of potential litigation costs, regulatory and execution risks, and uncertainty surrounding Unicycive’s lead drug candidate. One notice cited a 39.1% share-price decline on June 30 following unusually heavy trading, intensifying investor concern. Levi and Korsinsky lawsuit reminder

Institutional Trading of Unicycive Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of UNCY. Seven Fleet Capital Management LP raised its holdings in shares of Unicycive Therapeutics by 85.6% in the 2nd quarter. Seven Fleet Capital Management LP now owns 103,400 shares of the company’s stock worth $521,000 after purchasing an additional 47,700 shares during the period. Bank of New York Mellon Corp purchased a new stake in shares of Unicycive Therapeutics in the 2nd quarter valued at about $248,000. Bank of America Corp DE boosted its position in shares of Unicycive Therapeutics by 19,327.6% during the 1st quarter. Bank of America Corp DE now owns 29,530 shares of the company’s stock valued at $194,000 after acquiring an additional 29,378 shares during the last quarter. Renaissance Technologies LLC bought a new stake in shares of Unicycive Therapeutics during the 1st quarter valued at about $161,000. Finally, Dimensional Fund Advisors LP purchased a new position in shares of Unicycive Therapeutics during the first quarter worth about $940,000. 40.42% of the stock is owned by hedge funds and other institutional investors.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.